NCT04171986

Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis

Mecapegfilgrastim Prevents Prospective, One-arm, Single-center Study of Concurrent Hyperfractionated Chemoradiotherapy With Neutropenia and Radiation Esophagitis in Limited-stage Small Cell Lung Cance

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 93 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Mecapegfilgrastim	Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.

Timeline

• Start date: 2019-11-10
• Primary completion: 2021-10-31
• Completion: 2021-10-31
• First posted: 2019-11-21
• Last updated: 2019-11-21

Locations

1 site across 1 country: China